ABSTRACT
Since the emergence of coronavirus disease 2019, a large spectrum of clinical manifestations following this acute viral infection has been reported especially autoimmune manifestations and inflammatory disorders. However, a causal link has not yet been established. Herein, we reported a case of pulmonary mediastinal sarcoidosis following coronavirus disease 2019 infection. A 41-year-old woman with no clinical or radiographic symptoms or signs of sarcoidosis prior to coronavirus disease 2019 infection developed dyspnea, cough, and fatigue, a few months after discharge. A chest thoracic scan performed 3 months after hospital discharge showed regression of ground-glass opacities with the appearance of pulmonary micronodules. Clinical examination and spirometry were normal. The evolution was marked by progressive worsening of dyspnea and significant weight loss. A chest thoracic scan performed 6 months after discharge showed bilateral and symmetrical hilar and mediastinal and paratracheal lymphadenopathy. Bronchoalveolar lavage with cell count showed a lymphocytosis of 19.5% and a CD4/CD8 T cell ratio of 2.2. Endobronchial lung biopsy revealed noncaseating epithelioid granulomas. Sputum culture excluded tuberculosis. The diagnosis of pulmonary-mediastinal sarcoidosis was made. She was treated with an oral corticosteroid. The patient showed significant improvement during the 3-month follow-up period. Post-coronavirus disease sarcoidosis is very rare. Complementary studies are needed to discern the link between these diseases.Copyright © Author(s).
ABSTRACT
Introduction: Data on the short, medium and long term after covid-19 in adults is lacking and is sometimes discordant. The aim of our study was to describe the clinical profile of patients with symptoms lasting for more than 4 weeks after covid-19 and to determine the frequency of each symptom according to the time of infection. Method(s): Cross-sectional study including 1124 NH patients who reported having had covid-19 at least 1 month ago or more and who self-reported their symptoms prospectively in an online questionnaire. Result(s): A total of 861(76.6%) patients reported persistent symptoms, of which 728(84.5%) for>=3 months, 649(75.3%) for>=6 months, 268(31.1%) for>=12 months. The mean age was 30.5+/-9.4 years with a sex ratio at 0.12. Most of them was non-smokers (83.5 %), did not drink alcohol (87.4%) and had no medical history (81.3%). Overweight or obesity was found in 33.6% of them. Covid-19 was virologically confirmed in 75.3% of cases. Long covid was characterized by cognitive disorders, asthenia, psychological troubles, dysosmia, dysgeusia and sleeping disorders (Table 1). Conclusion(s): Symptoms can last for several months and even more than 1 year after covid-19 in NH patients with an improvement over time. Cognitive disorders and asthenia are main patients' complaint. Dyspnea and chest pain are less common. (Figure Presented).
ABSTRACT
Declaration de liens d'interets: Les auteurs declarent ne pas avoir de liens d'interets. Copyright © 2022
ABSTRACT
Declaration de liens d'interets: Les auteurs declarent ne pas avoir de liens d'interets. Copyright © 2022
ABSTRACT
Introduction Il n’y a aucune preuve sur le rôle de la prise antérieure des corticostéroïdes inhalés (CSI) dans l’évolution de la COVID-19. Notre objectif était d’évaluer l’influence des CSI dans le pronostic de la COVID-19. Méthodes Une étude rétrospective étalée sur 4 mois, incluant les dossiers de patients hospitalisés dans notre service pour infection COVID-19. Nous avons divisé notre population en 2 groupes G1 : patients ayant une maladie respiratoire chronique sous CSI et G2 : patients n’ayant pas reçu de CSI. Résultats Au total, 100 patients étaient inclus dans notre étude. Quatorze pour cent des patients étaient sous CSI. Le sex-ratio dans le G1 était de 0,4 versus 1,8 dans le G2. L’âge moyen était de 57 ans dans le G1 contre 62,17 ans dans le G2. La moyenne de la saturation initiale en oxygène dans le G1 était de 84,92 % contre 85,62 % dans le G2. La moyenne du degré d’atteinte radiologique dans le G1 était de 50 % contre 44,4 % chez le G2. Il n’y avait pas de corrélation entre la prise de CSI et le degré d’atteinte radiologique (p=0,437) et la saturation initiale en oxygène (IOS) (p=0,738). Conclusion Dans notre étude, nous n’avons pas trouvé d’influence des CSI sur le pronostic de la COVID-19.
ABSTRACT
Introduction: Coronavirus pandemic has been the subject of a large number of publications, some of which have shown an increased risk of contracting Covid-19 in carriers of blood group A. Aims: In this study we looked at the profile of blood group phenotype of a series of Tunisian patients with covid-19 admitted to Abderrahman Mami hospital in Ariana. Methods: Our study included 51 Tunisian patients with SARS-CoV-2 infection admitted to Abderrahmane Mami hospital between late march 2020 and early May 2020. The distribution of blood groups in Covid-19 patients was compared with that of a control group of 1506 patients with no Covid-19 infection as well as with the distribution of blood groups in a population of 63375 voluntary blood donors. Results: Our series, although limited in size, showed a higher prevalence of blood group A among Covid-19 patients, statistically significant compared to ABO blood group distribution among Tunisian blood donors and among a control group of patients without Covid -19. Conclusion: these results are in line with data from the literature, particularly on larger series in China.